Zogenix Inc

NASDAQ:ZGNX   10:15:05 AM EDT
26.00
0.00 (-0.02%)
Products, Regulatory

Zogenix Submits New Drug Application For Fintepla (Fenfluramine) In Japan For The Treatment Of Epileptic Seizures Associated With Dravet Syndrome

Published: 12/21/2021 13:15 GMT
Zogenix Inc (ZGNX) - Zogenix Submits New Drug Application for Fintepla® (fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated With Dravet Syndrome.
Zogenix - Submission Supported by Study 3, Double-blind, Placebo-controlled Phase 3 Study, of 143 Children & Young Adults With Dravet Syndrome.
Zogenix - If Approved in Japan, Fintepla Will Be Commercialized in Japan Through Co's Exclusive Distribution Agreement With Nippon Shinyaku.